ReviewTranslational cancer research2020
Review of non-invasive urinary biomarkers in bladder cancer.
Review in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review.Current oncology (Toronto, Ont.) · 2024Pooled it
- Paired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Study.Journal of clinical medicine · 2026Article
- Deep Learning-Assisted Accuracy Improvement in Bladder Cancer Staging of Spectrum-Aided Visual Enhanced Cystoscopy Images.Biosensors · 2026Article
- Diagnostic and Prognostic Non-Invasive Markers in Bladder Cancer.Diagnostics (Basel, Switzerland) · 2026Review
- Complement system in cancer: friend or foe of immunotherapy.Journal for immunotherapy of cancer · 2026Review
- Urine-Based Approaches for Screening, Diagnosis, and Surveillance of Urothelial Carcinoma.Journal of personalized medicine · 2026Review
- The promise of deep urine proteomics for diagnosis of cancer, neurologic, and metabolic diseases.PloS one · 2026Article
- Article
- The diagnostic performance of a noninvasive urine-based methylation biomarkers Vimentin/POU4F2 to detect bladder carcinoma.BMC cancer · 2025Article
- Neolactotetraosylceramide enables urinary detection of bladder cancer.Cell reports. Medicine · 2025Article
- Review
- Evaluation of expression profiles of APOA4, CEACAM1, CD147, DJ-1/PARK7, Gamma-synuclein, S100A1, and Stathmin-1 in urothelial carcinomas using immunohistochemical assays.Frontiers in oncology · 2025Article
- Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.Translational cancer research · 2024Review
- Urinary DNA-methylation and protein biomarkers identify urothelial carcinoma among other genitourinary diseases and cancer-free individuals.Journal of translational medicine · 2024Article
- Circular STAG2 RNA Modulates Bladder Cancer Progression via miR-145-5p/TAGLN2 and Is Considered as a Biomarker for Recurrence.Cancers · 2024Article
- Bladder cancer biomarkers: current approaches and future directions.Frontiers in oncology · 2024Review
- Novel urine-based DNA methylation biomarkers for urothelial bladder carcinoma detection in patients with hematuria.Arab journal of urology · 2023Article
- The miRNome of canine invasive urothelial carcinoma.Frontiers in veterinary science · 2022Article
- Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations.Expert review of molecular diagnostics · 2021Review
- Circulating Cell-Free DNA in Liquid Biopsies as Potential Biomarker for Bladder Cancer: A Systematic Review.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BC) is the sixth-most prevalent cancer. The standard diagnostic tool of BC is cystoscopy, whereas cystoscopy has several disadvantages in terms of symptomatic invasiveness and operator-dependency. The urinary markers are attractive because the testing is non-invasive and cost-efficient, and sample collection is easy. Urinary marker is thereby a good tool to detect exfoliated tumor cell in the urine samples for the diagnosis and therapeutic surveillance of BC to supplement the limitations of the cystoscopy. However, they are not recommended as a population-based screening tool because of the low rate of BC prevalence. Although both cystoscopy and urine cytology improve BC diagnostic power, the field still needs additional non-invasive, cost-effective, and highly sensitive and specific diagnostic tools. Various urinary markers with different mechanisms and different targets have been developed and under investigation in these days. However, the accuracy of the urinary marker including its sensitivity and specificity is the most important factor for the diagnosis and surveillance in cancer that this review deals with multiple FDA-approved and non-FDA approved commercialized urinary markers with their accuracy in different purposes for BC. We then discuss more about the potential candidate targets for the future urinary markers in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.